GADD45β loss ablates innate immunosuppression in cancer

Daniela Verzella, Jason Bennett, Mariafausta Fischietti, Anil K. Thotakura, Camilla Recordati, Fabio Pasqualini, Daria Capece, Davide Vecchiotti, Daniel D'Andrea, Barbara Di Francesco, Marcella De Maglie, Federica Begalli, Laura Tornatore, Salvatore Papa, Toby Lawrence, Stuart J. Forbes, Antonio Sica, Edoardo Alesse, Francesca Zazzeroni, Guido Franzoso

Research output: Contribution to journalArticlepeer-review


T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overcoming immune escape. Here, we identify a myeloid-intrinsic mechanism governed by the NF-κB effector molecule GADD45b that restricts tumor-associated inflammation and T-cell trafficking into tumors. In various models of solid cancers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of proinflammatory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing oncogenesis. Our results provide a basis to interpret clinical evidence that elevated expression of GADD45B confers poorclinical outcomes in most human cancers. Furthermore, they suggest a therapeutic target in GADD45β for reprogramming TAM to overcome immunosuppression and T-cell exclusion from the TME.

Original languageEnglish
Pages (from-to)1275-1292
Number of pages18
JournalCancer Research
Issue number5
Publication statusPublished - Mar 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'GADD45β loss ablates innate immunosuppression in cancer'. Together they form a unique fingerprint.

Cite this